Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05160415 · ClinicalTrials.gov registry record · Phase 1
A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy
A Phase 1 study, sponsored by Edgewise Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT05160415 is a Phase 1 study that has completed, run by Edgewise Therapeutics. The registered enrollment target is 12 participants.
The verdict
NCT05160415, a Phase 1 study, has completed, sponsored by Edgewise Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The ARCH study was an open-label, single-center, Phase 1b study of sevasemtem (EDG-5506) to assess the safety and pharmacokinetics (PK) of sevasemten in adults with Becker muscular dystrophy (BMD). Sevasemten is an investigational product intended to protect and improve function of dystrophic muscle fibers.
Interventions
- DRUG Sevasemten
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-12-28 |
| Est. Completion | 2024-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05160415
The ClinicalTrials.gov registry entry for NCT05160415 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Edgewise Therapeutics, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sevasemten is the first listed.
NCT05160415 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05160415 about?
NCT05160415 is a clinical study titled "A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy". The ARCH study was an open-label, single-center, Phase 1b study of sevasemtem (EDG-5506) to assess the safety and pharmacokinetics (PK) of sevasemten in adults with Becker muscular dystrophy (BMD). Sevasemten is an investigational product intended to protect and improve function of dystrophic muscl...
What is the current status of trial NCT05160415?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2021-12-28. Estimated completion is 2024-03-01.
What interventions are being tested in trial NCT05160415?
The interventions under investigation include: Sevasemten (DRUG).
Who is sponsoring clinical trial NCT05160415?
This trial is sponsored by Edgewise Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.